Suppr超能文献

成人注意力缺陷/多动障碍治疗改变的原因:一项图表回顾研究。

Reasons for treatment changes in adults with attention-deficit/hyperactivity disorder: a chart review study.

机构信息

Otsuka Pharmaceutical Development & Commercialization, Inc., 508 Carnegie Center, Princeton, NJ, 08540, USA.

Center for Psychiatry and Behavioral Medicine, 7351 Prairie Falcon Rd STE 160, Las Vegas, NV, 89128, USA.

出版信息

BMC Psychiatry. 2022 Jun 3;22(1):377. doi: 10.1186/s12888-022-04016-9.

Abstract

BACKGROUND

Adults with attention-deficit hyperactivity disorder (ADHD) often cycle through multiple treatments for reasons that are not well documented. This study analyzed the reasons underlying treatment changes among adults treated for ADHD in a real-world setting.

METHODS

Data were collected via an online reporting form completed by eligible physicians between October and November 2020. Data for adult patients in the United States who were diagnosed with ADHD and initiated a treatment regimen within 1 to 5 years of chart abstraction were obtained. Reason for a treatment change was described for a randomly selected regimen episode, which spanned from treatment initiation until the earliest among treatment add-on/switch or discontinuation, death, or date of chart abstraction. The overall rate of ADHD/treatment-related complications were also described. Physician satisfaction with current treatment options for adult ADHD and opinions on areas for improvement were assessed.

RESULTS

Data on 320 patients were reported by 152 physicians specializing in psychiatry (40.1%), pediatrics (25.0%), family medicine (21.7%), and internal medicine (13.2%). Patients had a mean age of 29.3 years; most were diagnosed with ADHD as adults (57.5%) and within the previous 5 years (56.5%). Selected treatment regimens included stimulants (79.1%), nonstimulants (14.7%), and combination therapy (5.6%) for an average duration of 1.9 years. Among patients with treatment discontinuation (N = 59), the most common reasons for discontinuation were suboptimal symptom management (55.9%), occurrence of ADHD/treatment-related complications (25.4%), and patient attitude/dislike of medication (25.4%). The main reasons for other key treatment changes were inadequate/suboptimal management of symptoms and cost considerations. Over 40% of patients had ≥ 1 documented ADHD/treatment-related complication, irrespective of whether they led to a treatment change. One in 5 physicians (19.8%) were very dissatisfied, moderately dissatisfied, or neither satisfied nor dissatisfied with current treatment options for ADHD in adults; the top 3 suggested improvements were lower risk of abuse (71.7%), longer effect duration (65.1%), and fewer ADHD/treatment-related complications (61.2%).

CONCLUSIONS

The top reasons for treatment changes among adults with ADHD are lack of efficacy and ADHD/treatment-related complications, highlighting the importance of developing more effective and safer treatments to alleviate the burden of ADHD.

摘要

背景

患有注意力缺陷多动障碍(ADHD)的成年人经常因未充分记录的原因而多次更换治疗方案。本研究分析了在现实环境中治疗 ADHD 成人的治疗方案改变的原因。

方法

通过在线报告表收集数据,该报告表由 2020 年 10 月至 11 月期间符合条件的医生填写。获取了在美国接受 ADHD 诊断并在图表提取前 1 至 5 年内开始治疗方案的成年患者的数据。对于随机选择的治疗方案,描述了治疗方案改变的原因,该方案从治疗开始一直持续到治疗添加/转换或停药、死亡或图表提取的最早时间。还描述了 ADHD/治疗相关并发症的总体发生率。评估了医生对成人 ADHD 现有治疗方案的满意度以及对改进领域的意见。

结果

152 名专门从事精神病学(40.1%)、儿科学(25.0%)、家庭医学(21.7%)和内科(13.2%)的医生报告了 320 名患者的数据。患者的平均年龄为 29.3 岁;大多数患者被诊断为成年 ADHD(57.5%)和过去 5 年内(56.5%)。选定的治疗方案包括兴奋剂(79.1%)、非兴奋剂(14.7%)和联合疗法(5.6%),平均持续时间为 1.9 年。在治疗中断(N=59)的患者中,停药的最常见原因是症状管理不理想(55.9%)、出现 ADHD/治疗相关并发症(25.4%)和患者对药物的态度/不喜欢(25.4%)。其他主要治疗方案改变的原因是症状管理不足/不理想和费用考虑。超过 40%的患者有≥1 次记录的 ADHD/治疗相关并发症,无论是否导致治疗方案改变。五分之一的医生(19.8%)对成人 ADHD 的当前治疗方案非常不满意、不满意或既不满意也不不满意;前 3 个建议的改进措施是降低滥用风险(71.7%)、延长作用持续时间(65.1%)和减少 ADHD/治疗相关并发症(61.2%)。

结论

ADHD 成年人治疗方案改变的主要原因是疗效不足和 ADHD/治疗相关并发症,这突出了开发更有效和更安全治疗方法的重要性,以减轻 ADHD 的负担。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39c0/9164343/2621ab111b96/12888_2022_4016_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验